Jonas Zenger
Associate
Jonas Zenger’s practice covers all aspects of EU and UK competition law, digital markets regulation, and foreign investment control.
Jonas’ experience includes abuse of dominance, cartel, State aid, and merger control matters as well as private damages litigation. He also advises on the UK’s national security and public interest regimes. Jonas has represented clients across a range of industries in proceedings before the European Commission, the UK Competition and Markets Authority, and the Competition Appeal Tribunal. He has written on sustainability and alternative policy objectives in competition law.
Prior to joining the firm in 2022, Jonas trained at a major international law firm for two years in London and Paris.
Notable Experience
-
Broadcom, a global technology company, on the UK merger control aspects of its $69 billion acquisition of VMware.
-
Google on the Competition and Markets Authority’s market investigation relating to mobile browsers and cloud gaming.
-
Amazon on its defense of collective proceedings before the Competition Appeal Tribunal relating to certain agreements with Apple.
-
The Walt Disney Company on the global merger control and antitrust aspects of its media and entertainment joint venture with Reliance Industries.
-
OpenText on the EU and UK merger control and UK national security aspects of its $6 billion acquisition of Micro Focus.
-
Thales on the UK national security aspects of its $3.6 billion acquisition of Imperva.
SELECTED ACTIVITIES
trigger- Member, Association for the Study of Antitrust Law (Studienvereinigung Kartellrecht)
Publications
“United Kingdom,” co-author, Lexology’s In-Depth: Cartels and Leniency, 12th edition, March 2024
“Court of Appeal upholds extraterritorial information-gathering powers,” co-author, Cleary Antitrust Watch blog, January 22, 2024
“Competition Appeal Tribunal Sets Aside CMA’s First Antitrust Fine for Most Favoured Nation Clauses in its Compare the Market Decision,” co-author, Cleary Antitrust Watch blog, August 12, 2022
“Unfair Play: UK CMA Fines Pharmaceutical Companies for Excessive Prices,” co-author, Cleary Antitrust Watch blog, August 1, 2022
“Public interest considerations in merger control: the case of biodiversity,” European Competition Law Review, 2018, 39(7), 336-340.